

PRESS RELEASE
18 September 2020



Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at Business Weekly Awards 2020

- *Mogrify recognized for furthering life science discovery for the benefit of human healthcare through direct cellular conversion technology*
- *Co-founder and CSO receives award celebrating his achievements in establishing Mogrify*

Cambridge, UK, 18 September 2020: Mogrify Limited (Mogrify®), a UK company aiming to transform the development of *ex vivo* cell therapies and pioneer the field of *in vivo* reprogramming therapies, today announced it had won the AstraZeneca Life Science Innovation category of the Business Weekly Awards. The award commends Mogrify in applying its proprietary direct cellular conversion technology to further the cause of life science discovery for the benefit of human healthcare. Prof. Julian Gough, Co-founder and CSO of Mogrify, received the Cambridge Enterprise Academic Entrepreneur of the Year award in recognition of his work as a life science innovator and founder of Mogrify.

Mogrify's proprietary direct cellular conversion technology determines the conversion factors required to convert (*ex vivo* or *in vivo*) any target cell type from any source cell type. The Company is deploying this platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to address diseases with a high unmet clinical need, such as in ophthalmological, immunological, hematological, and other disease areas.

Prof. Gough is a leading bioinformatician and biotech entrepreneur who led the development and application of the Mogrify platform, which utilizes a systematic big-data approach (Rackham *et al.*, Nature Genetics, 2016) developed over a 10-year period via a multi-national research collaboration. Graduating with a PhD in molecular biology from the University of Cambridge, Julian became Professor of Bioinformatics at the University of Bristol and is now Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge. He has also successfully started a number of biotech companies.

Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: *"Our team are committed to transforming healthcare for indications of high unmet clinical need. The award for Life Science Innovation attests to the potential of Mogrify's platform and pioneering team to overcome safety, efficacy and scalability challenges for cell therapies and we are honored to have this recognized by the judges at this year's esteemed business awards.*

Julian is an outstanding scientist and entrepreneur who has worked tirelessly to advance Mogrify technology and drive its therapeutic application forward, paving the way for future treatments and inspiring those who work alongside him."

Professor Julian Gough, Co-founder and CSO, Mogrify, said: *“Following on from our previous success in the ‘Disruptive Technology’ category at last year’s Business Weekly Awards, I am delighted to see Mogrify go from strength to strength and achieve success again in 2020.*

I am immensely proud to have been named ‘Academic Entrepreneur of the Year’ and would like to thank my peers who have supported me throughout my career and Mogrify’s talented team for their dedication and hard work in pioneering novel cell therapies.”

Since February 2019, Mogrify has raised over \$20 million USD in seed and series A rounds and \$2.5 million USD in grant funding, and has grown to a headcount over 60 of scientific, operational, and commercial staff.

For further information on Mogrify’s technology and leadership team, please visit:

<https://mogrify.co.uk/cellular-conversion-technology/#our-science>

https://mogrify.co.uk/leadership-team/#_leaders

ENDS

Notes to Editors



*Prof. Julian Gough,
Co-founder and CSO,
Mogrify*



*Dr. Darrin M. Disley, OBE,
CEO,
Mogrify*

For high-resolution and alternate images please contact Zyme Communications.

For further information please contact:

Mogrify

Darrin M. Disley, PhD, OBE

Tel: + 44 (0)1223 734154

Email: darrin@mogrify.co.uk

Zyme Communications (media inquiries)

Michelle Ricketts, PhD

Tel: +44 (0)7789 053885

E-mail: michelle.ricketts@zymecommunications.com

Westwicke, an ICR Company (investor inquiries)

Stephanie Carrington

Tel: +1 (646) 277-1282

Email: stephanie.carrington@icrinc.com

To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please [click here](#).

About Mogrify www.mogrify.co.uk

Mogrify® has developed a proprietary direct cellular conversion technology that utilizes a systematic big-data approach (Rackham *et al.*, Nature Genetics, 2016) developed over a 10-year period via a multi-national research collaboration. By deploying next-generation sequencing, gene regulatory and epigenetic network data, the platform enables the prediction of the transcription factors (or small molecules) and culture medium conditions required to produce (*ex vivo* or *in vivo*) any target cell type from any source cell type.

The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether effecting a direct transdifferentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of cell therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.

Uniquely positioned to address a regenerative medicine market estimated to be worth \$39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, and out-licensing of novel cell conversions. Based in Cambridge, UK, the Company has raised over \$20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.

Follow Mogrify on Twitter [@Mogrify_UK](#) and LinkedIn [@Mogrify](#)